Castedal M - Search Results

1

Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study.

Åberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, Bennet W, Olausson M, Line PD, Nordin A, Bergquist A, Boberg KM, Castedal M, Pedersen CR, Isoniemi H. Åberg F, et al. Among authors: castedal m. Hepatology. 2015 Feb;61(2):668-77. doi: 10.1002/hep.27538. Epub 2015 Jan 5. Hepatology. 2015. PMID: 25266201

2

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.

Castedal M, Siewert-Delle A, Olausson M, Friman S. Castedal M, et al. Transplant Proc. 2003 Mar;35(2):820-1. doi: 10.1016/s0041-1345(03)00085-x. Transplant Proc. 2003. PMID: 12644153 No abstract available.

3

[Liver dialysis using MARS in acute hepatic failure. Promising results in a pilot setting].

Felldin M, Friman S, Olausson M, Bäckman L, Castedal M, Larsson B, Henriksson BA, Siewert-Delle A. Felldin M, et al. Among authors: castedal m. Lakartidningen. 2003 Nov 20;100(47):3836-8, 3841. Lakartidningen. 2003. PMID: 14719235 Swedish.

4

Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism.

Björnsson E, Olsson J, Rydell A, Fredriksson K, Eriksson C, Sjöberg C, Olausson M, Bäckman L, Castedal M, Friman S. Björnsson E, et al. Among authors: castedal m. Scand J Gastroenterol. 2005 Feb;40(2):206-16. doi: 10.1080/00365520410009591. Scand J Gastroenterol. 2005. PMID: 15764153

5

Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis.

Castedal M, Felldin M, Bäckman L, Olausson M, Friman S. Castedal M, et al. Transplant Proc. 2005 Oct;37(8):3313-4. doi: 10.1016/j.transproceed.2005.09.018. Transplant Proc. 2005. PMID: 16298583

6

MELD [corrected] score in patients accepted for liver transplantation 1994 to 2004.

Flodén A, Castedal M, Friman S, Olausson M, Backman L. Flodén A, et al. Among authors: castedal m. Transplant Proc. 2006 Oct;38(8):2673-4. doi: 10.1016/j.transproceed.2006.07.030. Transplant Proc. 2006. PMID: 17098035

7

Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation.

Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL; Swedish Internal Medicine Liver Club. Prytz H, et al. Among authors: castedal m. Hepatology. 2006 Dec;44(6):1572-80. doi: 10.1002/hep.21433. Hepatology. 2006. PMID: 17133469

8

Calculation and comparison of the model for end-stage liver disease (MELD) score in patients accepted for liver transplantation in 1999 and 2004.

Flodén A, Castedal M, Friman S, Olausson M, Backman L. Flodén A, et al. Among authors: castedal m. Transplant Proc. 2007 Mar;39(2):385-6. doi: 10.1016/j.transproceed.2007.01.013. Transplant Proc. 2007. PMID: 17362737

9

Long-term follow-up of living liver donors.

Castedal M, Andersson M, Polanska-Tamborek D, Friman S, Olausson M, Fehrman-Ekholm I. Castedal M, et al. Transplant Proc. 2010 Dec;42(10):4449-54. doi: 10.1016/j.transproceed.2010.09.114. Transplant Proc. 2010. PMID: 21168716

10

Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.

Jørgensen KK, Lindström L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM. Jørgensen KK, et al. Among authors: castedal m. Scand J Gastroenterol. 2012 Sep;47(8-9):1021-9. doi: 10.3109/00365521.2012.685754. Epub 2012 May 14. Scand J Gastroenterol. 2012. PMID: 22577871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page